Case Report: Treatment of Widespread Nodular Post kala-Azar Dermal Leishmaniasis with Extended-Dose Liposomal Amphotericin B in Bangladesh: A Series of Four Cases

Am J Trop Med Hyg. 2017 Oct;97(4):1111-1115. doi: 10.4269/ajtmh.16-0631. Epub 2017 Aug 18.

Abstract

Post kala-azar dermal leishmaniasis (PKDL) is a skin manifestation which usually appears after visceral leishmaniasis. It is now proved that PKDL patients serve as a reservoir for anthropometric leishmanial transmission. Hence, to achieve the kala-azar elimination target set by the World Health Organization in the Indian Subcontinent, PKDL cases should be given priority. The goal of treatment for PKDL should be early reepithelizlization and rapid cure, but unfortunately this has been difficult to achieve, especially for patients with severe lesions. Therefore, we describe here four cases of PKDL who had widespread nodular and macular lesions and were treated with two cycles of LAmB doses with 20 mg/kg body weight divided into four equal doses (each dose contains 5 mg/kg) administered every alternate day. This treatment schedule achieved 100% treatment success with the minimal safety concern.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amphotericin B / therapeutic use*
  • Antiprotozoal Agents / therapeutic use*
  • Bangladesh
  • Female
  • Humans
  • Leishmania / drug effects*
  • Leishmaniasis, Cutaneous / drug therapy*
  • Leishmaniasis, Visceral / drug therapy*
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Antiprotozoal Agents
  • Amphotericin B